Iran approves import, manufacture of Russia's Covid-19 vaccineIran approves import, manufacture of Russia's Covid-19 vaccine
Criminal – Drug trafficking – High seas – Massachusetts Lawyers Weekly
BJP blames Congress for Republic Day protest violence
Mumbai's coronavirus recoveries exceed daily case countUntitled CarouselUntitled Carousel
Austria and Greece take €3.5bn each in hectic euro market
Liverpool MP calls for vaccine rollout improvements amid worries over supply
Whatley Manor receives Michelin’s ‘green star’
Costco COVID Vaccine Registration Latest As Stores Prepare for Appointments
Kotoko report referee Emmanuel Tampuri to Ghana FA – Ghana Visions
Redmi 9T Disrupts the Smartphone Segment with Exceptional Performance and Multi-day Battery Life – Manila Bulletin
Number of pigs killed by African swine fever in Tanzania rises to 1,155 - Xinhua
Parallel SSA structure for Zuma set up by former spy boss, Zondo commission hears
Spain vaccine crisis: Madrid cancels rollout for TWO WEEKS
Biden COVID-19 plan looks at safety as students, teachers defy rules
Sandra Lillian Robinson
Rana Kapoor: ED arrests Yes Bank co-founder Rana Kapoor in fresh money laundering case
Longhorns Staff Tracker: Sarkisian Hires Another From SEC As Chief Of Staff
Nick Knowles hits out at Tesco over 'stingy' Clubcard points rule
Bengaluru airport to reschedule flights during Aero India
Bulgaria's vice president tests positive for coronavirus
Another Winter Storm Looks Likely This Weekend
Novavax bosses cash out for $46 million with COVID-19 vaccine trials still under way By Reuters

To be sure, last year Novavax awarded more than $85 million worth of stock options to executives, including $41.Executives at Emergent BioSolutions Inc, Pfizer and Johnson & Johnson, also recipients of federal funds, sold $24 million, $10 million and $4 million worth of stock, respectively, according to Accountable.Moderna executives sold $166 million worth, according to Accountable.Pfizer Inc's vaccine was the first to be approved by the United States on Dec.
Novavax, meanwhile, announced last month that it had begun a late-stage trial of its COVID-19 vaccine in the United States, after delaying it twice due to issues in scaling up its manufacturing.Early-stage data from Novavax's small clinical trial of its vaccine have shown it produced high levels of virus-fighting antibodies and the company has already inked supply deals for it with countries including Japan, Canada, Australia and the UK as well as with the United States.